Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study. Issue 1 (31st December 2023)

• Record Type: Journal Article
• Authors: Rossi, Ernesto; Boldrini, Luca; Maratta, Maria Grazia; Gatta, Roberto; Votta, Claudio; Tortora, Giampaolo; Schinzari, Giovanni
• Is Part Of: Human vaccines & immunotherapeutics. Volume 19:Issue 1(2023)
• Publication Date: 2023-12-31
• Subjects: Radiomics -- features -- renal cell carcinoma -- immunotherapy -- anti-PD-1 -- anti-CTLA4 -- nivolumab -- ipilimumab -- pembrolizumab -- predictive factor; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2023.2172926
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Immunotherapy has become a cornerstone for the treatment of renal cell carcinoma. Nevertheless, some patients are resistant to immune checkpoint inhibitors. The possibility to identify patients who cannot benefit from immunotherapy is a relevant clinical challenge. We analyzed the association between several radiomics features and response to immunotherapy in 53 patients treated with checkpoint inhibitors for advanced renal cell carcinoma. We found that the following features are associated with progression of disease as best tumor response: F_stat.range ( p < .0004), F_stat.max ( p < .0007), F_stat.var ( p < .0016), F_stat.uniformity ( p < .0020), F_stat.90thpercentile ( p < .0050). Gross tumor volumes characterized by high values of F_stat.var and F_stat.max (greater than 60, 000 and greater than 300, respectively) are most likely related to a high risk of progression. Further analyses are warranted to confirm these results. Radiomics, together with other potential predictive factors, such as gut microbiota, genetic features or circulating immune molecules, could allow a personalized treatment for patients with advanced renal cell carcinoma.